One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
A systematic review of the potential consequences of abnormal serum levels of vitamin B6 in people living with Parkinson's disease
Joseph S. Modica a,1, Catherine D´ery b,1, Ryan Canissario a, Eric Logigian a, Deana Bonno a, Michael Stanton a, Nicolas Dupr´e b, Michael P. McDermott c, Manon Bouchard b, Anthony E. Lang d, Karlo J. Lizarraga
doi : 10.1016/j.jns.2023.120690
Volume 450, 15 July 2023, 120690
The prevalences of polyneuropathy and epilepsy are higher in people living with Parkinson's disease (PwPD) when compared to older adults. Vitamin B6 is widely available and affordable. PwPD are at higher risk of having abnormal serum levels of vitamin B6, which are associated with polyneuropathy and epilepsy that are potentially preventable and treatable.
Sex-dependent outcomes of recanalization-treated acute ischemic stroke patients at Shamir (Assaf Harofeh) medical center, Israel, 2011–2020
Itzhak Kimiagar a,1, Fikri Khiri a,1, Sigal Tal b, Ronen Levite a, Shani Kalmanovich-Avnery a, Rina Aroesty a, Sarah Bhonkar a, Jochay Wainstein a, Gilad Kenan a, Nitai Shimon a, Ahmed Khadija a, Neta Agajani a, Sofia Galinskaya a, Sharon Wolfson a, Zoya Haitov c, Eran Kalmanovich d, Daniel Trotsky e, Eduard Ilgiyaev f,2, Carmel Armon
doi : 10.1016/j.jns.2023.120674
Volume 450, 15 July 2023, 120674
Risk of optic neuritis in type 2 diabetes mellitus: A nationwide cohort study
Ga-In Lee a,b, Kyungdo Han c, Kyung-Ah Park d,*, Sei Yeul Oh
doi : 10.1016/j.jns.2023.120673
Volume 450, 15 July 2023, 120673
Associations between cognitive function and a range of significant life events in an elderly essential tremor cohort study
Diane S. Berry a,*, Diep Nguyen a, Stephanie Cosentino b,c, Elan D. Louis
doi : 10.1016/j.jns.2023.120675
Volume 450, 15 July 2023, 120675
Identifying specific myelopathy etiologies in the evaluation of suspected myelitis: A retrospective analysis
Diane S. Berry a,*, Diep Nguyen a, Stephanie Cosentino b,c, Elan D. Louis
doi : 10.1016/j.jns.2023.120677
Volume 450, 15 July 2023, 120677
The distribution of transcallosal inhibition to upper extremity muscles is altered in chronic stroke
Leticia Hayes a,1, Myriam Taga a,1, Charalambos C. Charalambous b,c, Sharmila Raju a, Jing Lin d, Heidi M. Schambra
doi : 10.1016/j.jns.2023.120688
Volume 450, 15 July 2023, 120688
Histopathological reaction in the vestibule after cochlear implantation in Macaca fascicularis.
Raquel Manrique-Huarte *, Octavio Garaycochea, Daniella Parillis Troconis, Nicol´as P´erez-Fern´andez, Manuel Manrique
doi : 10.1016/j.jns.2023.120672
Volume 450, 15 July 2023, 120672
Pressure reactivity index for early neuroprognostication in poor-grade subarachnoid hemorrhage
Jason J. Chang a,b,*, David Kepplinger c, E. Jeffrey Metter d, Daniel R. Felbaum e, Jeffrey C. Mai e, Rocco A. Armonda e, Edward F. Aulisi
doi : 10.1016/j.jns.2023.120691
Volume 450, 15 July 2023, 120691
Elevated brain derived neurotrophic factor in plasma and interleukin-6 levels in cerebrospinal fluid in meningitis compared to cerebral malaria
Monique F. Stins a,*,1, Agnes Mtaja b, Evan Mulendele b, Daniel W. Mwimbe b, Gabriel Pinilla c,d, Mable Mutengo b,2, Carlos A. Pardo c, James Chipeta
doi : 10.1016/j.jns.2023.120663
Volume 450, 15 July 2023, 120663
Neural antibody testing for autoimmune encephalitis: Impact of Autoimmune Neurology approval process on test utilization☆
Samir Alkabiea, Liju Yangb, Adrian Budhram
doi : 10.1016/j.jns.2023.120676
Volume 450, 15 July 2023, 120676
Marked central canal T2-hyperintensity in MOGAD myelitis and comparison to NMOSD and MS
Lauren M. Webb a, Laura Cacciaguerra a, Karl N. Krecke b, John J. Chen a,c, Elia Sechi a, Vyanka Redenbaugh a, Divyanshu Dubey a,d, Sean J. Pittock a,d, Eoin P. Flanagan
doi : 10.1016/j.jns.2023.120687
Volume 450, 15 July 2023, 120687
Natalizumab extended-interval dosing in a real-life setting
Natalizumab is a high-efficacy therapy for recurrent multiple sclerosis (RMS) with a four-week administration interval. Controlled trials have shown that extending this interval to six weeks led to better safety without increasing the risk of relapse. We aimed to analyze the safety of extending the natalizumab interdose interval from 4 to 6 weeks in a real-life setting.
doi : 10.1016/j.jns.2023.120689
Volume 450, 15 July 2023, 120689
A case of Balò's concentric sclerosis showing the attenuation of the Balò lesion after ofatumumab treatment: A case report
Daisuke Suzukia, Yoshihiro Suzukia, Daisuke Satoa, Kenji Kikuchia, Masahiro Akasakab, Akiko Nishidac, Kazuhiko Satod, Shingo Koyamae, Ichiro Nakashimad, Yasuyuki Ohta
doi : 10.1016/j.jns.2023.120694
Volume 450, 15 July 2023, 120694
